RT Journal Article
SR Electronic
T1 UV-C irradiation is highly effective in inactivating and inhibiting SARS-CoV-2 replication
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.05.20123463
DO 10.1101/2020.06.05.20123463
A1 Bianco, Andrea
A1 Biasin, Mara
A1 Pareschi, Giovanni
A1 Cavalieri, Adalberto
A1 Cavatorta, Claudia
A1 Fenizia, Claudio
A1 Galli, Paola
A1 Lessio, Luigi
A1 Lualdi, Manuela
A1 Redaelli, Edoardo
A1 Saulle, Irma
A1 Trabattoni, Daria
A1 Zanutta, Alessio
A1 Clerici, Mario
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.05.20123463.abstract
AB The potential virucidal effects of UV-C irradiation on SARS-CoV-2 were experimentally evaluated for different illumination doses and virus concentrations (1000, 5, 0.05 MOI). Both virus inactivation and replication inhibition were investigated as a function of these parameters. At a virus density comparable to that observed in SARS-CoV-2 infection, an UV-C dose of just 3.7 mJ/cm2 was sufficient to achieve a 3-log inactivation, and complete inhibition of all viral concentrations was observed with 16.9 mJ/cm2. These results could explain the epidemiological trends of COVID-19 and are important for the development of novel sterilizing methods to contain SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research has been carried out using internal funds of INAF and University of Milano.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Milano INAFAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results are reported in the paper and in the annexed supplementary material